Zeng Y, Guo T, Zhou Y, Zhao Y, et al. Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters. BMC Cancer 2022;22:198.
PMID: 35189835